

Amendment Under 37 C.F.R. § 1.111
US Application No. 09/674,377

Attorney Docket No. Q61434

AMENDMENTS TO THE DRAWINGS

Submitted herewith are replacement sheets for Figures 1B, 9, 10, and 12B.

REMARKS

In this Amendment, claims 1-4, 6, 12-16, 20 and 28-37 are amended, and claims 5, 7-11, and 21-27 are canceled. After entry of this Amendment, claims 1-4, 6, 12-16, 19-20, and 28-37 will be pending in this Application, and of these, claims 1-4, 6, 12-15, 19-20, 28-36 are under examination.

Rejoinder of claims 16 and 37 is requested upon allowance of the claims directed to the elected invention.

I. AMENDMENTS TO THE APPLICATION

(A) Amendments to the Specification

Submitted herewith is a clean copy and marked-up copy of a Substitute Specification to address the objections raised at pages 3 and 4 of the Office Action. The Substitute Specification incorporates the Article 34 Amendments made in corresponding the PCT application.

Also submitted herewith is a Substitute Sequence Listing (including a hard copy and a computer readable copy), and replacement sheets for Figures 1B, 9, 10, and 12B.

Entry of the Substitute Specification, Substitute Sequence Listing, and Replacement Drawings into the application is requested.

The Substitute Specification, the Substitute Sequence Listing and Replacement Drawings contain no new matter.

(B) Amendments to the Claims

The claims have been amended to recite: “a polypeptide having the amino acid sequence PyrGlu³² to Val⁴⁷⁸ of human hepatocyte growth factor (HGF),” and to recite that the polypeptide

“has a deletion of amino acids 162 to 166 of human HGF.” Support in the specification can be found in the sequence listing filed with the application, and page 18 of the original English language specification.

The claims have also been amended to recite: “a polypeptide having an amino acid sequence derived from the amino acid sequence of (a) by the deletion, substitution or addition of one or several amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.” Support can be found in the specification at page 17, last line from the bottom of the page.

The term “prophylaxis” has been removed from claims 15, 16, 28, 29, 30, and 33-36.

Other minor amendments have been made to the claims for clarity and consistency.

No new matter has been introduced.

Entry of this Amendment is requested.

II. PRIORITY DOCUMENT

The Examiner is respectfully requested to confirm whether the certified copy of the priority document has or has not been received.

The Examiner is requested to obtain the certified copy of the priority document from the International Bureau, if it has not yet been received.

III. RESPONSE TO OBJECTIONS

(A) At page 2 of the Office Action, the Examiner objects to Figures 1B, 9, 10 and 12B as being of inadequate quality.

Replacements Figures are submitted herewith to address this objection.

(B) At page 3 of the Office Action, the Examiner objects to the title of the invention as not being sufficiently descriptive.

The title has been amended to read: “Neovascularization Inhibitors Derived From HGF And Methods Involving the Same.”

(C) At page 3 of the Office Action, the Examiner notes that the word “endothelial” is misspelled at page 13/3, and that the specification does not contain consecutive page numbering.

The typographic error and page numbering, as well as any other errors of a typographical or grammatical nature that the Applicant or the Applicant’s representative are aware of, have been corrected in the Substitute Specification submitted herewith.

(D) At page 4 of the Office Action, the Examiner objects to claims 1-2, 12-15, 28, 31, and 34, and page 30 of the specification, for not referring to a sequence identifier.

The claims have been amended to recite “human” hepatocyte growth factor to clarify the amino acid numbering in the claims. A sequence identifier for human HGF is unnecessary.

Further, the specification has been amended, and a Substitute Sequence Listing submitted, to identify the peptide of RKRRNTIHEF as SEQ ID NO: 3.

(E) At page 4 of the Office Action, the Examiner objects to claims 28, 31 and 34 because the word “hepatocyte” is misspelled.

This typographical error has been corrected.

IV. RESPONSE TO CLAIM REJECTION UNDER 35 USC §101

At page 5 of the Office Action, claim 19 is rejected under 35 USC §101, because the claim allegedly reads on a product of nature.

This rejection is respectfully traversed, because the claimed polypeptide is not a product of nature. The claimed polypeptide is a mutant polypeptide, having a five amino acid deletion, that does not naturally exist.

The Examiner's attention is respectfully directed to page 18, line 20 to page 19, line 16, of the specification describing the polypeptide of SEQ ID NO: 2 (del 5), for example, as being prepared chemically or through gene recombination techniques.

In addition, HGF/NK4 is not naturally produced *in vivo*, but may be produced, for example, *ex vivo* by enzymatic cleavage of HGF with elastase.

Withdrawal of this rejection is requested.

V. RESPONSE TO CLAIM REJECTIONS UNDER 35 USC §112, 2ND PARAGRAPH

At page 5 of the Office Action, claims 1-7, 9, 10, 12-15, 19-26 and 28-36 are rejected under 35 USC §112, second paragraph, as being indefinite for the following reasons.

(1) The Examiner states that the notation "PyrGlu³²~Val⁴⁷⁸" renders claims 1-2, 12-15, 28, 31 and 34, indefinite because: (i) the numbering is allegedly meaningless without reference to a particular sequence; (ii) the numbers are internally inconsistent, and (iii) the symbol "~" to show a range of amino acids is not conventional.

The claims have been amended to recite "a polypeptide having the amino acid sequence PyrGlu³² to Val⁴⁷⁸ of human hepatocyte growth factor (HGF)...." These amendments thus clarify the claim language.

With respect to the internal consistency of the numbering, the carboxyl terminal valine, of SEQ ID NO:2 for example, corresponds to position 478 of human HGF. That is, the position

number of the valine residue retains the natural position number of 478, despite the five amino acid deletion, or other modifications within the scope of the claim. Such is believed to be the clearest way to recite the invention, and is consistent with the art accepted nomenclature for naming polypeptides harboring deletions or other modifications.

(2) The Examiner contends that claims 1, 2, 12-15, 28, 31 and 34 are indefinite because they include “deletion, substitution or addition of one or more amino acids” with no upper limit on the number of such modifications.

The claims have been amended to recite that “a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or “several” amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.”

It is respectfully submitted that the Examiner’s interpretation of the claim language has having “no upper limit to the number of modification” is unreasonable. The claimed polypeptide is required to have the activities recited in the claims, and is fragment of human HGF. The protein has been known and studied for decades, allowing one of skill in the art to make several modifications to the protein of the invention, and consistent with the goals described in the application as filed. See pages 6-9 of the original specification.

(3) The Examiner states that claims 7, 9, 10, 22, 24 and 26 are indefinite because it is not clear what further limitation is implied by the recited intended use.

These claims have been canceled

(4) The Examiner states that claim 22 is generally unclear.

Claim 22 has been canceled.

(5) The Examiner states that the term “tumor” in claim 24 renders this claim indefinite.

Claim 24 has been canceled.

(6) The Examiner states that claim 33 is indefinite because there is no basis in claims 31 or 32 for “prophylaxis or therapy” or for the phrase “wherein tumor is....”

Claim 33 has been amended to read: “The method for inhibition of tumor growth or metastasis of claim 31 or 32, wherein the subject has lung cancer or mammary cancer.”

Withdrawal of the Section 112, second paragraph rejections is requested.

VI. RESPONSE TO CLAIM REJECTIONS UNDER 35 USC §112, 1ST PARAGRAPH

(1) At pages 6 and 7 of the Office Action, claims 1, 2, 12-15, 28, 31 and 34 are rejected under 35 USC §112, first paragraph, as not being in compliance with the written description requirement for the following reasons.

The Examiner states that claims 1, 2, 12-15, 28, 31 and 34 lack an adequate written description because they include the “deletion, substitution or addition of one or more amino acids” with no upper limit on the number of modifications. The Examiner believes that the specification does not provide a sufficient description of other muteins within the scope of the claims.

The claims have been amended to recite “a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or “several” amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.”

It is respectfully submitted that the Examiner's interpretation of the claim language has having "no upper limit to the number of modification" is unreasonable. The claimed polypeptide is required to have the recited activity, and is fragment of human HGF. The protein has been known and studied for decades, allowing one of skill in the art to make several modifications to the protein of the invention, and consistent with the goals described in the application as filed.

Withdrawal of this rejection is requested.

(2) At pages 7 and 8 of the Office Action, the Examiner rejects claims 7, 9, 10, 14, 15, 21, 22, 25, 26, 28-30 and 33-36 under 35 USC §112, first paragraph, as not being adequately enabled by the specification.

Specifically, while the Examiner acknowledges that the specification is enabling for compositions and methods for antagonizing HGF to inhibit or treat neovascularization, including inhibition of tumor growth or metastasis, the Examiner believes that the specification does not reasonably provide enablement for prophylaxis.

The term "prophylaxis" has been removed from the claims.

Withdrawal of this rejection is requested.

VII. RESPONSE TO OBVIOUSNESS-TYPE DOUBLE PATENTING REJECTION

(1) At pages 9-10 of the Office Action, claims 1-5, 7, 9, 10, 12-15, 28-32 and 34-36 are rejected for obviousness-type double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 6,855,685.

(2) At page 10 of the Office Action, claims 6-7 and 19-26 are rejected for obviousness-type double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 6,855,685 in view of EP 0461560 (EP'560).

Applicants will file a terminal disclaimer for U.S. Patent No. 6,855,685 in due course to render these rejections moot.

VIII. RESPONSE TO CLAIM REJECTIONS UNDER 35 USC §102

At page 11 of the Office Action, claims 1-5, 7, 9 and 10 are rejected under 35 USC §102(b) as being anticipated by Date et al., FEBS Lett. (1997).

Specifically, the Examiner contends that Date et al. disclose HGF/NK4, which is SEQ ID NO:1 of the present application. The Examiner notes that Date et al. test the mitogenic activity of HGF/NK4 on rat hepatocytes in primary culture (page 4 and Figure 3).

The amended claims recite a polypeptide having a deletion of amino acids 162-166 of HGF, which is not taught by Date et al.

Accordingly, Date et al. do not teach the claimed neovascularization inhibitor, and thus withdrawal of this rejection is requested.

IX. RESPONSE TO CLAIM REJECTIONS UNDER 35 USC §103(a)

(1) At pages 11-12, claims 6-7 and 19-26 are rejected under 35 USC §103(a) as being obvious over Date et al., in view of EP'560.

(2) At pages 12-13 of the Office Action, claims 12-15 and 28-36 are rejected under 35 USC §103(a) as being obvious over U.S. Patent No. 6,207,152 to Schwall et al., in view of Date et al.

Submitted herewith is a Rule 132 Declaration by Dr. Kunio Matsumoto. The Declaration shows the inhibitory effect of HGF/NK4 harboring a deletion of amino acids 162-166 of human HGF ("HGF/NK4 (del 5)"), on the growth of human dermal microvascular endothelial cells. More specifically, the Declaration shows that HGF/NK4 (del 5) inhibits HGF-induced growth of vascular endothelial cells, *and* inhibits growth induced by other vascular endothelial cell growth factors such as bFGF and VEGF.

This biological effect was entirely unexpected, and is an extremely important feature of the invention.

More specifically, since neovascularization is induced by various growth factors such as HGF, bFGF, and VEGF (see the attached Rule 132 Declaration and Example 7 of the specification), an effective neovascularization inhibitor must inhibit the growth of vascular endothelial cells induced by all of HGF, bFGF and VEGF.

In this respect, antagonist activity via the c-Met/HGF receptor, as observed with HGF/NK4, does not allow one of ordinary skill to predict whether NK4/HGF does, or does not, inhibit the growth of vascular endothelial cells induced by bFGF and VEGF, because the growth of vascular endothelial cells induced by bFGF and VEGF presumably involves receptors other than c-Met/HGF receptor.

Further, submitted herewith is a copy of Kuba, et al., Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells, *Biochem. Biophys. Res. Commun.*, 2000; 279: 846-852.

Kuba et al. state at page 850, right column, that “antagonistic effects of NK4 on HGF are not involved in its angioinhibitory action.” Further, and also at page 850, Kuba et al. state: “We now have the first evidence that K1-4, which has no antagonistic action in HGF, retained inhibitory effects on endothelial proliferation and migration mediated by bFGF, VEGF, and HGF, in a similar manner to NK4.”

Kuba et al., which was published after the present application’s priority date of April 28, 1998, disclose only NK4 and K1-K4, but do not disclose HGF/NK4 (del 5) of the claimed invention.

Thus, Kuba et al. further show that the inhibitory action of HGF/NK4(del 5) on the growth of vascular endothelial cells induced by bFGF and VEGF is unexpected, and is advantageous for neovascularization inhibitors.

Withdrawal of the Section 103(a) rejections are requested.

X. CONCLUSION

In view of the above, reconsideration of this application is requested. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Amendment Under 37 C.F.R. § 1.111
US Application No. 09/674,377

Attorney Docket No. Q61434


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Mark L. Hayman
Registration No. 51,793

Date: September 18, 2006



In re appln of Toshikazu NAKAMURA
Appln. No.: 09/674,377
Confirmation No.: 7003
Filed: October 30, 2000
Substitute Specification (marked up version)

NEOVASCULARIZATION INHIBITORS DERIVED FROM HGF AND METHODS INVOLVING THE SAME

TECHNICAL FIELD

The present invention relates to neovascularization inhibitors. More particularly, the invention relates to a neovascularization inhibitor (anti-neovascularization composition) which comprises a protein having a defined regional sequence of the α -chain of hepatocyte growth factor (hereinafter referred to sometimes briefly as HGF) as an active ingredient.

The neovascularization inhibitor of the present invention finds application, based on its inhibitory effect on neovascularization, as a prophylactic or therapeutic agent for various diseases associated with abnormal angiogenesis, such as rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, senile macular degeneration and hypercicatrization in wound healing.

BACKGROUND ART

Neovascularization is a phenomenon such that the vascular endothelial cells, mainly of venules, form a *de novo* vasculature in response to some stimulus or other. In the normal state of a living body, this phenomenon is indispensable for sustained metabolism of tissues and for functional homeostasis of the body and is generally observed in the process of wound healing, growth of fetal lungs, and evolution of luteinization.

Meanwhile, it is well known that an abnormal angiopoiesis is involved in various diseases inclusive of inflammatory diseases. For example, such diseases as proliferating diabetes, psoriasis vulgaris, rheumatoid arthritis, diabetic retinopathy, senile macular degeneration, over_cicatrization in wound healing, etc. and the metastasis and recurrence of

carcinomas are reportedly caused by hyperplasia of blood vessels, particularly peripheral capillary vessels [Polverini PJ., *Crit. Rev. Oral. Biol. Med.*, 1995, 6(3), pp.230-247, Review: Forkman J., *Nature Med.*, 1995, 1(1), pp.27-31].

Therefore, as prophylactic or therapeutic drugs for those diseases, a variety of anti-neovascularization drugs comprising compounds having neovascularization-inhibitory activity as active ingredients have been developed to this day.

The present invention has for its object to provide a novel anti-neovascularization factor. Another object of the present invention is to provide a neovascularization inhibitor useful for the prevention and treatment of said various diseases arising from hyperplasia of blood vessels.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A is a reversed phase high-performance liquid chromatogram (reversed phase HPLC) (C4) of elastase-treated HGF and Fig. 1B is an electrophoretogram (under reducing and non-reducing conditions) of peak fractions on said reversed phase HPLC.

Fig. 2 is a schematic representation of the structures of the α - and β -chains of HGF and the structure of the PyrGlu³² ~ Val⁴⁷⁸ region of HGF (HGF/NK4) which has been excised by elastase treatment.

Fig. 3 A and B show the dose-dependent rates of binding of ¹²⁵I-HGF and ¹²⁵I-HGF/NK4, respectively, to the rat liver plasma membrane. The insets in Fig. 3 A and B show the rates of binding of ¹²⁵I-HGF and ¹²⁵I-HGF/NK4 to said rat liver plasma membrane in Scatchard plots. Fig. 3 C is a diagram showing the rates of binding of unlabeled HGF and unlabeled HGF/NK4 to the rat liver plasma membrane in the presence of ¹²⁵I-HGF (cf. Example 2).

Fig. 4 is a diagram showing the presence or absence of mitogenic activity in HGF and HGF/NK4 (A) and a diagram showing the antagonistic action of HGF/NK4 against the mitogenic activity of HGF. The mitogenic activity information was generated by assaying the DNA synthesis of rat primary-culture hepatocytes. Specifically, Fig. 4 A shows the DNA synthesis of hepatocytes in the presence of HGF or HGF/NK4 and Fig. 4 B shows the effect of HGF/NK4 on the DNA synthesis of hepatocytes in the presence of 60 pM HGF or 1.5 nM epidermal growth factor (EGF) [cf. Example 3].

Fig. 5 is a diagram showing the inhibitory effect of HGF/NK4 on the proliferation of human lung microvascular endothelial cells in the presence or absence (None) of bFGF, HGF or VEGF [Example 7].

Fig. 6 is a diagram showing the inhibitory effect of HGF/NK4 on the proliferation of human skin microvascular endothelial cells in the presence or absence (None) of bFGF, HGF or VEGF [Example 7].

Fig. 7 is a diagram showing the effects of HGF/NK4 (NK4 on the drawing) and anti-HGF antibody (α -HGF Ab on the drawing) on the proliferation of human capillary vessel endothelial cells in the presence of 5% fetal bovine serum (FBS), 5% FBS+bFGF, 5% FBS+VEGF or 5% FBS+HGF [cf. Example 9 A].

Fig. 8 is a diagram showing the effects of HGF/NK4 (NK4 on the drawing) and anti-HGF antibody (α -HGF Ab on the drawing) on the migration of human capillary vessel endothelial cells in the presence of 1% fetal bovine serum (FBS), 1% FBS+bFGF, 1% FBS+VEGF or 1% FBS+HGF [cf. Example 9 B].

Fig. 9 is a set of photographs, in lieu of a drawing, which shows the results of observation of the neovascularization-inhibitory effect of HGF/NK4 on chick embryonic chorioallantoic membrane with a stereoscopic microscope.

Fig. 10 is a photograph, in lieu of a drawing, which shows the inhibitory effect of HGF/NK4 on tumor neovascularization as assayed by an immuno histochemical method.

Fig. 11 indicates that HGF/NK4 has the action to inhibit growth of Lewis lung tumor cells, wherein A is a diagram showing the time course of the volume of a transplanted tumor mass and B is a histogram showing the weight of the transplanted tumor at day 28.

Fig. 12 A is a histogram indicating that HGF/NK4 has the action to inhibit metastasis of Lewis lung tumor cells [Reference Example 1] and Fig. 12 B is a photograph, in lieu of a drawing, which shows the metastasis of the tumor to the lung, indicating clearly that whereas a plurality of lung metastatic foci are present in the saline-treated control group, substantially no lung metastatic foci are detected in the HGF/NK4-treated group.

Fig. 13 indicates that HGF/NK4 has the action to inhibit the growth (A) and metastasis (B) of Jyg mammary tumor cells; A shows the time course of the volume of a transplanted tumor mass and B shows the number of metastatic foci.

DISCLOSURE OF INVENTION

Searching for a novel neovascularization inhibitor in earnest with the above object in mind, the inventors of the present invention found that a protein containing a defined region of the α -chain of hepatocyte growth factor (HGF) has the action to significantly inhibit neovascularization and have accordingly developed the present invention.

HGF is the very polypeptide which the inventors discovered in 1984 as a novel growth factor for hepatic parenchymal cells (Nakamura, T. et al., *Biochem Biophys Res Commun.*, 1984, 122, pp. 1450-1459). Subsequent studies by the present inventors revealed that HGF is a heterodimer consisting of an α -chain having a molecular mass of about 69 kDa and a β -chain having a molecular mass of about 34 kDa and has a unique domain

structure comprising an N-terminal hairpin domain and 4 Kringle domains in the α -chain and a serine protease-like domain in the β -chain (Nakamura T., et al., *Nature* 1989, 342, pp. 440-443). Though, as of the time of its discovery, HGF was considered to be a growth factor with highly specificity to hepatocytes as the substantive entity of liver regeneration factor, the subsequent studies made since 1989 when recombinant HGFs became available revealed that HGF acts also as a potent mitogen for many kinds of epithelial cells in addition to hepatocytes (Nakamura T., *Princess Takamatsu Symp.*, 1994, 24, pp. 195-213. Review). Moreover, the results of further investigations indicated that, in addition to the above cell growth-regulating function, HGF not only has the function of a motogen enhancing cell motility (T. Nakamura, *Prog. growth Factor Res.*, 3, pp. 67-85, 1991) but also has novel biological activities inclusive of tumor suppressant activity which inhibits proliferation of many kinds of tumor cells (Higashio K, et al., *Biochem Biophys Res Commun.*, 1990, July 16, 170(1), pp.397-404).

Furthermore, it was elucidated, in 1991, that the functional receptor having a high affinity for HGF is a protooncogene product (c-met product: c-Met) (Bottaro D. P., et al., *Science*, 1991, Feb., 15, 251(4995), pp. 802-804; Naldini L, et al., *Oncogene*, 1991 Apr, 6(4), pp.501-504), and the present inventors discovered that the N-terminal hairpin domain and first and second Kringle domains of the α -chain are the minimum domains binding to said c-Met/HGF receptor (Matsumoto, K. et al., *Biochem. Biophys. Res. Commun.*, 1991 Dec., 16, 181(2), pp.691-699).

The present inventors did a further study on the heels of the above series of research into HGF and arrived at the novel finding that a polypeptide having said N-terminal hairpin and first through fourth Kringle domains of the α -chain has antagonistic activity against the

c-Met/HGF receptor-mediated action of HGF and confirmed that said polypeptide has the action to significantly suppress the neovascularization-inducing action of HGF.

The present invention has been developed on the basis of years of those studies on HGF.

The present invention, therefore, is directed to the following neovascularization inhibitors 1 ~ 6.

1. A neovascularization inhibitor comprising the following polypeptide (a) or (b) as an active ingredient.

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor.

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence of (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

2. A neovascularization inhibitor comprising the following polypeptide (a) or (b) as an active ingredient:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF and inhibitory action against the growth of vascular endothelial cells induced by bFGF and/or VEGF.

3. A neovascularization inhibitor as set forth in paragraph 1 or 2 wherein said polypeptide has at least one hairpin domain and 4 Kringle domains.

4. A neovascularization inhibitor as set forth in paragraph 1 or 2, wherein said polypeptide is one obtainable by elastase digestion of hepatocyte growth factor.

5. A neovascularization inhibitor comprising the polypeptide defined by SEQ ID NO:1 and a pharmaceutically acceptable carrier.

6. A neovascularization inhibitor comprising the polypeptide defined by SEQ ID NO:2 and a pharmaceutically acceptable carrier.

The present invention is further directed to the following medically or pharmacologically useful agents 7~11.

7. A prophylactic or therapeutic agent for a disease associated with abnormal angiopoiesis which comprises the polypeptide as set forth in paragraph 1 or 2 and a pharmaceutically acceptable carrier.

8. A prophylactic or therapeutic drug as set forth in paragraph 7 wherein said disease associated with abnormal angiopoiesis is selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eye, angiofibroma, benign tumors and wound granulation.

9. A prophylactic or therapeutic drug for a disease arising from over stimulation of endothelial cells which comprises the polypeptide as set forth in paragraph 1 or 2 and a pharmaceutically acceptable carrier.

10. A prophylactic or therapeutic drug as set forth in paragraph 9 wherein said disease arising from over stimulation of endothelial cells is selected from the group consisting of enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and over cicatrisation.

11. A conception-regulating drug comprising the polypeptide as set forth in paragraph 1 or 2 and a pharmaceutically acceptable carrier.

The present invention is further directed to the following medically or pharmacologically useful treatment methods 12~16.

12. A method of inhibiting neovascularization which comprises administering to a subject a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence of (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

13. A method of inhibiting neovascularization which comprises administering to a subject a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF and inhibitory action against the growth of vascular endothelial cells induced by bFGF and/or VEGF.

14. A method for prophylaxis or therapy of a disease associated with abnormal angiopoiesis which comprises administering a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF to a subject in whom a prophylactic or therapeutic treatment for said disease is indicated.

15. A method for prophylaxis or therapy of a disease associated with abnormal angiopoiesis which comprises administering a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF and inhibitory action against the growth of vascular endothelial cells induced by bFGF and/or VEGF to a subject in whom a prophylactic or therapeutic treatment for said disease is indicated.

16. The method for prophylaxis or therapy as set forth in paragraph 14 or 15 wherein said disease is any disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint,

angiogenic diseases of the eye, angiofibroma, benign tumors, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and over cicatrisation.

In a further aspect, the present invention is directed to the use of the following polypeptide 17~18.

17. Use of the following polypeptide (a) or (b) for the production of a neovascularization inhibitor:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

18. Use of the following polypeptide (a) or (b) for the production of a neovascularization inhibitor:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF),

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids, and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF and inhibitory action against the growth of vascular endothelial cells induced by bFGF and/or VEGF.

Representation of amino acids, peptides, nucleotide sequences and others by abbreviations in this specification is principally in conformity with the nomenclature recommended by IUPAC and IUPAC-IUB and the rules set forth in the "Guideline for Preparation of a Specification or the Equivalent Referring to a Nucleotide Sequence or an

Amino Acid Sequence" (March 1997, The Examination Standards Office, Coordination Division, the Patent Office of Japan).

Furthermore, the amino acid numbers and positions as mentioned in this specification are based on the amino acid sequence of prepro-HGF (Nakamura T., et al., Nature 1989, 342, pp. 440-443).

In the context of this invention, PyrGlu means pyroglutamate, which is a modified amino acid residue, and PyrGlu³² signifies that, based on the amino acid sequence of prepro-HGF, the 32nd amino acid residue from the N-terminus is pyroglutamate.

The neovascularization inhibitor (anti-neovascularization composition) of the present invention contains as an active ingredient a polypeptide resulting from the α -chain of HGF and having neovascularization inhibitory activity.

The term "resulting from the α -chain of HGF" is used herein to mean that the entire region or fragments of the α -chain of HGF are contained, whether continuously or discontinuously.

The term neovascularization inhibitory activity means any action that suppresses neovascularization without regard to its mode or mechanism. ~~but, in~~ In a preferred sense, it means the action to suppress the neovascularization-inducing action of HGF. More preferably, it means the action to suppress the neovascularization-inducing action of HGF, VEGF or bFGF.

As polypeptides having such activity, there can be mentioned polypeptides having an affinity for the c-Met/HGF receptor, which is the receptor of HGF, and the action to competitively antagonize the binding of HGF to said receptor. The preferred are polypeptides which bind to the c-Met/HGF receptor to exhibit antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

The c-Met/HGF receptor-mediated action of HGF includes c-Met/HGF receptor tyrosine phosphorylating activity, motogenic activity, mitogenic activity and morphogenic activity [Jikken Igaku (Experimental Medicine), Vol. 11, No. 9 (1993)].

Therefore, the polypeptide for use in the present invention is a polypeptide which suppresses or inhibits any of such activities, more particularly a polypeptide having at least one action selected from among the action to suppress/inhibit the HGF-induced c-Met/HGF receptor tyrosine phosphorylation, the action to suppress/inhibit the motogenic activity of HGF, the action to suppress/inhibit the mitogenic activity of HGF and the action to suppress/inhibit the morphogenic activity of HGF. Preferably, a polypeptide having all of the above-mentioned actions can be mentioned.

As preferred examples of such polypeptide, there can be mentioned a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of HGF, more particularly a polypeptide having the amino acid sequence depicted in SEQ ID NO:1. In SEQ ID NO:1, "Xaa" represents "PyrGlu".

This polypeptide can be obtained basically by subjecting HGF to elastase treatment, and consists of the 447 amino acids in the N-terminal region of the α -chain of HGF. Therefore, like the α -chain of HGF, this particular polypeptide has the modified amino acid residue = pyroglutamate at the N-terminus and contains one N-terminal hairpin domain and 4 Kringle domains. In this specification, the above polypeptide is referred to sometimes as HGF/NK4.

As will be shown in the Example which appears hereinafter, this polypeptide exhibits said antagonistic activity by binding to the c-Met/HGF receptor in competition with HGF and has the action to suppress or inhibit the HGF-induced auto-tyrosine-phosphorylation of the c-Met/HGF receptor. Furthermore, this polypeptide has little mitogenic, motogenic or

morphogenic activities of its own and has the property to inhibit the mitogenic, motogenic and morphogenic activities of HGF.

However, the polypeptide for use as the active ingredient of the neovascularization inhibitor of the present invention is a polypeptide resulting from the α -chain of HGF and, inasmuch as it has the action to inhibit the neovascularization-inducing action of HGF, is not limited to said particular polypeptide shown in SEQ ID NO:1.

As specific examples of said polypeptide, there can be mentioned polypeptides having amino acid sequences derived from the amino acid sequence $\text{PyrGlu}^{32} \sim \text{Val}^{478}$ of HGF by the deletion, substitution or addition of one, a few or more amino acids and yet having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

More preferably, polypeptides equivalent or comparable to said HGF/NK4 in physiological activities (tyrosine phosphorylation inhibiting activity, anti-motogenic activity, anti-mitogenic activity, and anti-morphogenic activity) can be mentioned.

The extent of said "deletion, substitution or addition" of amino acids and the positions involved are not particularly restricted only if the mutant polypeptide still retains the above-mentioned physiological activities. By way of example, a polypeptide resulting from the deletion or addition of one or more than one (or several) amino acids in the N-terminal and/or C-terminal region of said HGF/NK4 and a polypeptide resulting from the deletion or addition of one or more than one (or several) amino acids in the intermediate region of HGF/NK4. Preferably, however, at least one hairpin domain and 4 Kringle domains, which characterize the structure of HGF/NK4, are substantially retained after the mutation.

As a corollary, as a typical mutant peptide, a polypeptide resulting from the substitution, deletion or addition of one or more than one (or several) of the amino acids in the region exclusive of said hairpin domain and 4 Kringle domain can be mentioned. As

specific examples of such mutant peptide, there can be mentioned a polypeptide [HGF/NK4 (del 5)] resulting from the deletion of 5 amino acids, namely amino acid Nos. 162~166 (amino acids Nos. 131~135 in SEQ ID NO:1), from the HGF/NK4 polypeptide, that it to say the polypeptide having the amino acid sequence depicted in SEQ ID NO:2.

HGF/NK4 or HGF/NK4 (del 5) for use in the present invention can be respectively produced chemically by a routine method for peptide synthesis or by a routine genetic engineering technique, on the basis of the amino acid sequence information given in SEQ ID NO:1 or 2 or the already-known gene (nucleotide) sequence of HGF.

Preferably, it can be obtained by enzymatic degradation of HGF.

The enzymatic degradation of HGF can be achieved by digesting HGF with an elastase or the like enzyme. Then, this enzymatic digest is purified by the conventional protein purification method, for example high-performance liquid chromatography or SDS-PAGE, and a polypeptide having a given molecular mass is isolated to acquire HGF/NK4. The molecular mass mentioned above may be about 65~69 kD, preferably about 67 kD, as determined by SDS-PAGE under reducing conditions and about 48~52 kD, preferably about 50 kD, as determined by SDS-PAGE under non-reducing conditions.

HGF for use in said enzymatic degradation is not particularly limited in terms of its source or preparation procedure.

For example, it can be obtained by extraction and purification from liver or other tissues, blood cells such as platelets, leukocytes, etc., plasma or serum of mammals inclusive of man (FEBS, 224, 312, (1987); Proc. Acad. Sci. USA, 86, 5844 (1989)) or by growing primary-culture HGF-producing cells or cell lines and separating and purifying HGF from the resulting culture. As a further alternative, a recombinant HGF can be acquired by a genetic engineering technique which may comprise cloning an HGF-encoding gene in a suitable

vector, introducing the vector into suitable host cells (e.g. animal cells) for transfection and harvesting the objective recombinant HGF from a culture supernatant of the resulting cells (e.g. Nature, 342, 440, 1989; JP 1993-111383A; JP 1991-255096A; Biochem., Biophys. Res. Commun., 163, 967, 1989, etc.). The HGF-encoding gene which can be used routinely includes HGF genes derived from mammals inclusive of humans, preferably the HGF gene of the human origin, more preferably human-derived recombinant HGF genes (JP 1993-111383A).

The so-called mutants constructed on the basis of the amino acid sequence of HGF/NK4, such as HGF/NK4 (del 5), can be prepared chemically by a method for peptide synthesis or by a genetic engineering technique starting with an HGF gene.

The technology for mutagenesis includes genetic engineering methods such as site-specific mutagenesis [Methods in Enzymology, 154: 350, pp. 367-382 (1987); ditto 100: 468 (1983);

Nucleic Acids Res., 12: 9441 (1984); Zoku Seikagaku Jikken Koza 1 "Idenshi Kenkyuho II" (Experimental Biochemistry Series 1 "Methods for Gene Research II") (edited by Japanese Biochemical Society), p105 (1986)], as well as the methods of chemical synthesis, such as the phosphotriester method and phosphoamidate method [J. Am. Chem. Soc., 89: 4801 (1967); do: 91: 3350 (1969); Science, 150: 178 (1968); Tetrahedron Lett., 22: 1859 (1981); do 24: 245 (1983)] and any combination of such techniques.

The neovascularization inhibitor of the present invention is not particularly restricted in dosage form and may be provided in a variety of dosage forms, namely oral preparations such as powders, fine granules, granules, tablets, pills, capsules, solutions, emulsions, suspensions, syrups, etc.; preparations for external application, such as ointments, creams, DDS patches, suppositories, etc.; ophthalmic preparations such as eyedrops, ophthalmic

ointments, etc.; injections and drip infusions. These dosage forms can be manufactured by the pharmaceutical procedures well established in the art.

Regarding the manufacture of tablets, the carrier that can be used includes various excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silica, etc.; binders such as simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.; disintegrators such as dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, calcium carbonate, polyethoxylated sorbitan fatty acid esters, sodium lauryl sulfate, stearyl monoglyceride, starch, lactose, etc.; disintegration inhibitors such as sucrose, stearic acid, cacao butter, hydrogenated oil, etc.; absorption promoters such as quaternary ammonium bases, sodium lauryl sulfate, etc.; humectants such as glycerin, starch, etc.; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silica, etc.; and lubricants such as purified talc, salts of stearic acid, boric acid powder, polyethylene glycol and so on. Furthermore, where necessary, tablets may be manufactured in the form of coated tablets, i.e., tablets carrying a conventional surface coating, such as sugar-coated tablets; gelatin-coated tablets; film-coated tablets, etc., or in the form of double-layered or multi layered tablets.

The carrier which can be used in the manufacture of pills include but is not limited to various excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc, etc.; binders such as gum arabic powder, tragacanth powder, gelatin, etc.; and disintegrators such as laminaran and agar, among others.

Capsules can be manufactured by the conventional method which comprises blending said peptide with various carrier substances such as those mentioned above and filling the mixture into hard gelatin capsule shells, soft gelatin capsule shells or the like.

For use in the manufacture of suppositories, the carrier includes polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin and semisynthetic glycerides, among others.

Injections can be manufactured by the conventional technology, for example by dissolving said polypeptide in a suitable solvent, sterilizing the solution for example by filtration, and distributing it into sterile vials. Such injections are preferably isotonic to blood, and the diluent which can be used for provision of such dosage forms includes but is not limited to sterile water, ethyl alcohol, macrogols, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyethoxylated sorbitan fatty acid esters. A sufficient amount of sodium chloride, glucose or glycerin to isotonize such injections may be included in formulations and the conventional solubilizer, buffer, local anesthetic and other additives may also be added.

For the manufacture of an ointment, the ointment base, stabilizer, lubricant, preservative, etc., which are usually employed for such peptides, are formulated and processed in the conventional manner to provide the objective product. The ointment base mentioned above includes liquid paraffin, white petrolatum, bleached beeswax, paraffin and so on. The preservative includes methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate and propyl p-hydroxybenzoate, among others.

Transdermal drug delivery systems can be prepared by spreading said ointment or an equivalent thereof in the form of a paste, cream or gel on the conventional support in the conventional manner. The suitable support includes a woven or nonwoven cloth of cotton, spun rayon or other chemical fiber or a flexible polyvinyl chloride, polyethylene, polyurethane or other sheet or foam sheet.

Furthermore, each of said various pharmaceutical preparations may be supplemented, where necessary, with various pharmaceutically acceptable additives such as a coloring agent, a preservative, a flavoring agent, a corrigent, a sweetener, etc. and/or other medicaments.

In pharmaceutical production runs, a stabilizer is preferably formulated. The stabilizer which can be used includes albumin, globulin, gelatin, mannitol, glucose, dextran and ethylene glycol, to mention but a few examples.

Solutions inclusive of parenteral preparations should be stored frozen or preferably supplied as lyophilized products. Lyophilized preparations are extemporaneously reconstituted with distilled water for injection or the like solvent vehicle.

The amount of the polypeptide to be formulated in the pharmaceutical composition of the present invention is not particularly restricted but can be liberally selected from a broad range. Generally, however, the recommended concentration in the composition is about 0.0002~0.2 (w/v) %, preferably about 0.001~0.1 (w/v) %.

The method of administering the pharmaceutical composition is not particularly restricted but can be judiciously selected with reference to the dosage form, patient factors such as age, sex, etc. and severity of illness, among other conditions. By way of illustration, parenteral preparations may be intravenously administered either independently or in admixture with the conventional glucose, amino acid or other infusion. Where necessary, such preparations may be administered alone intramuscularly, intradermally, subcutaneously or intraperitoneally.

The daily dosage of the neovascularization inhibitor of the present invention is dependent on the patient's condition, body weight, age, sex and other factors and cannot be stated in general terms. However, in terms of the amount of the polypeptide of the invention (HGF/NK4 or a mutein thereof), the recommended usual dosage for an adult human is about

0.01~100 mg/day and this dose may be administered in a single dose or in a few divided doses.

The neovascularization inhibitor of the present invention can be applied to the prophylaxis and therapy of a broad spectrum of diseases arising from vascular hyperplasia. Although such diseases are not particularly restricted, there can be mentioned rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eye (e.g. diabetic retinopathy, retinopathy of prematurity, senile macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, etc.), angiofibroma, benign tumors (e.g. hemangioma, acoustic neuroma, neurofibroma, trachoma, granuloma pyogenicum, etc.), hematopoietic malignancies such as leukemia, solid cancers, cancer metastasis and wound granulation, among others.

The neovascularization inhibitor of the present invention is further applicable broadly to the prophylaxis and therapy of diseases caused by an excessive or abnormal stimulation of the endothelial cells. Such diseases are not particularly restricted but include, among others, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma, and over-cicatrizization such as keloid.

Furthermore, the neovascularization inhibitor of the present invention finds application as a drug for conception control based on inhibition of the neovascularization necessary for implantation and finds application as a prophylactic or therapeutic drug for diseases accompanied by angiogenesis, such as cat scratch disease and ulcer, as an pathologic outcome.

BEST MODE FOR CARRYING OUT THE INVENTION

The following examples are intended to illustrate the present invention in further detail without delineating the technical scope of the invention. Thus, many modifications and changes can be made by those skilled in the art based on the disclosure in this specification without departing from the technical scope of the invention.

EXAMPLE 1: ISOLATION AND PURIFICATION OF HGF/NK4

CHO cells transfected with human HGF cDNA were cultured and the recombinant HGF was isolated and purified from the culture (Nature 342, pp.440-443 (1989); Biochem. Biophys. Res. Commun. 172; pp.321-327 (1990)). This recombinant HGF (900 mg) was digested with pancreatic elastase (Sigma) in 0.2 M Tris-HCl buffer (pH 8.8) at 37°C for 20 minutes (enzyme:substrate = 1:100). This digest was purified by reversed-phase high-performance liquid chromatography (HPLC; μ Bondapack C4 column, Waters Japan) on a gradient of 0.05% trifluoroacetic acid-acetonitrile. On the HPLC, three peaks were detected as shown in Fig. 1A.

Then, each of these peak fractions was subjected to SAS-PAGE and protein staining (Fig. 1B). It was found that a first peak is a polypeptide fragment having a molecular mass of 50 kD under nonreducing conditions and of 67 kD under reducing conditions; a second peak corresponds to the undigested heterodimer HGF consisting of an α -chain of 69 kD and a β -chain of 34/32 kD; and a third peak is a fragment having a molecular mass of 33/31 kD under nonreducing conditions and of 34/32 kD under reducing conditions.

In the above description, the expression $_/_$ kD indicates the existence of proteins of the same amino acid sequence but different molecular masses depending on differences in the appended sugar chain.

The foregoing indicated that, upon elastase treatment, HGF is digested into two fragments, namely a fragment (the first peak) comprising a major part of the α -chain but being slightly smaller than the full-length α -chain and a fragment (the third peak) consisting of part of the C-terminal sequence of the α -chain and the full-length β -chain.

For the amino acid sequencing of the purified fragments, the solvent was first evaporated off from each fraction of the eluate and the residue was dissolved in 0.1 M phosphate buffer (pH 7.3) containing 0.05% CHAPS (Sigma) and 1 M NaCl. The amino acid analysis was carried out using Automatic Protein Sequencer 492 (Applied Biosystem Inc.).

To begin with, the analysis for the N-terminal sequence of the first-peak fragment was attempted but failed, suggesting the likelihood that the N-terminus of this fragment was in the pyroglutamate form as it was the case with the N-terminus of HGF. Therefore, this fragment was first treated with pyroglutamate aminopeptidase and then analyzed for the N-terminal sequence. As a result, the sequence, as expressed in single capital letters, was found to be RKRRNTIHEF (SEQ ID NO:3) in agreement with the N-terminal amino acid sequence No. 2 ~ No. 11 of the α -chain. It was thus found that the N-terminal amino acid of this fragment was glutamine modified in the pyroglutamate form and the structure of the N-terminal region was identical with that of undigested HGF.

Then, for analysis of the C-terminus of this fragment, an amino acid analysis was carried out on the other fragment produced by elastase digestion (the third fragment) for the N-terminus of its partial α -chain. As a result, the amino acid sequence of the N-terminal region of this partial α -chain was found to correspond to the Asn⁴⁷⁹ ~ Ala⁴⁸⁸ of HGF. This finding indicated that the C-terminus of the first-peak fragment was Val⁴⁷⁸.

Based on the above results, it was clear that HGF, on elastase treatment, is digested into two fragments, one of which is a fragment consisting in the PyrGlu³² ~ Val⁴⁷⁸ region having the hairpin domain and 4 Kringle domains of HGF (HGF/NK4) while the other is a fragment consisting of part of the α -chain (16 amino acids starting with Asn⁴⁷⁹) and the β -chain (Fig. 2).

EXAMPLE 2: BINDING AFFINITY OF HGF/NK4 FOR CELL SURFACE RECEPTORS

Using the HGF/NK4 prepared in Example 1, its binding affinity for the cell surface receptor was investigated. As a control experiment, the binding affinity of HGF for the cell surface receptor was also investigated. In this connection, the HGF/NK4 and HGF were radio-labeled (¹²⁵I-HGF/NK4 and ¹²⁵I-HGF) by the chloramine-T method, and as the cell surface receptor sample, the plasma membrane prepared from the rat liver was used.

Scatchard analysis revealed that both HGF and HGF/NK4 bind to the cell surface receptors in a concentration-dependent manner up to 80 pM (Fig. 3 A and B), that the K_d and number of HGF receptors were 64.5 pM and 5478 sites/ng, respectively, and that the K_d and number of HGF/NK4 receptors were 486 pM and 6427 sites/ng, respectively.

Then, to investigate whether HGF/NK4 is a competitive antagonist of HGF, the liver plasma membrane (50 μ g) was incubated in the presence of ¹²⁵I-HGF alone (60 pM) or a mixture of ¹²⁵I-HGF and a varying amount of unlabeled HGF or unlabeled HGF/NK4. The membrane binding of ¹²⁵I-HGF was completely inhibited by the addition of unlabeled HGF and the 50% inhibitory concentration of unlabeled HGF was 60 pM. Unlabeled HGF/NK4 also inhibited the membrane binding of ¹²⁵I-HGF and the 50% inhibitory concentration of this HGF/NK4 was 600 pM, with the membrane binding of ¹²⁵I-HGF being completely inhibited at 60 nM [Fig. 3 C].

These results suggested that HGF/NK4 has an affinity for the c-Met/HGF receptor, although it is 8~10 times as low as that of HGF and, thus, is an antagonist of HGF.

EXAMPLE 3: MITOGENIC ACTIVITY OF HGF/NK4 AND THE INHIBITORY EFFECT OF HGF/NK4 ON THE MITOGENIC ACTIVITY OF HGF

The mitogenic activity of HGF/NK4 was evaluated by assaying the DNA synthesis of rat primary-culture hepatocytes. As a control experiment, the mitogenic activity of HGF was similarly evaluated (Nature 342, 440-443 (1989); Biochem. Biophys. Res. Commun. 181, 691-699 (1991)).

The data are presented in Fig. 4 A. It can be seen from the diagram that whereas HGF promoted the DNA synthesis of hepatocytes dose-dependently, HGF/NK4 did not promote the DNA synthesis even at a high concentration of 100 nM.

On the other hand, when HGF/NK4 was added to an HGF-containing culture medium so that both HGF and HGF/NK4 would be present, HGF/NK4 dose-dependently inhibited the DNA synthesis promoted by HGF, causing a substantially complete inhibition at 60 nM (Fig. 4 B). In contrast, HGF/NK4 showed no inhibitory effect on the DNA synthesis promoted by epidermal growth factor (EGF) (Fig. 4 B).

These results indicated that although HGF/NK4 has no mitogenic activity of its own, it has an action to specifically inhibit the mitogenic action of HGF.

EXAMPLE 4 MITOGENIC ACTIVITY OF HGF/NK4 AND THE ANTAGONISTIC ACTION OF HGF/NK4 AGAINST MITOGENIC ACTIVITY OF HGF

Using MDCK cells, the renal tubule-derived normal epithelial cells, the mitogenic activity of HGF/NK4 was evaluated.

The MDCK cells formed a confluent mass of colonies in an HGF-free control medium but addition of HGF (22 pM) to the medium resulted in increased motility of MDCK

cells and dispersion of the cells. In contrast, HGF/NK4 did not disperse the cells, with the mutual contact of cells being well maintained. Moreover, when MDCK cells were cultured in the presence of both HGF and HGF/NK4, HGF/NK4 inhibited the HGF-induced cell dispersion.

These results indicated that although HGF/NK4 has no motogenic activity of its own, it has an action to inhibit the motogenic activity of HGF.

EXAMPLE 5 MORPHOGENIC ACTIVITY OF HGF/NK4 AND THE ANTAGONISTIC ACTION OF HGF/NK4 AGAINST THE MORPHOGENIC ACTIVITY OF HGF

To explore whether HGF/NK4 inhibits the morphogenic activity of HGF, MDCK cells, the renal tubule-derived normal epithelial cells, were cultured in collagen gel in the presence of HGF and/or HGF/NK4.

While the MDCK cells formed spherical cell masses in an HGF-free control medium, addition of HGF (55 pM) to the medium induced formation of a branched luminal structure. Addition of HGF/NK4 (55 nM) to this system did not induce such a luminal structure. Moreover, when MDCK cells were grown in the presence of both HGF and HGF/NK4, the cells remained in the form of masses without induction of a luminal structure.

The above results indicated that although HGF/NK4 has no morphogenic activity of its own, it has an action to inhibit the morphogenic activity of HGF.

EXAMPLE 6: INHIBITORY EFFECT OF HGF/NK4 ON HGF-INDUCED C-MET TYROSINE PHOSPHORYLATION

The lung tumor cell line A549 is known to have c-Met/HGF receptors expressed and to show enhanced tyrosine phosphorylation of c-Met in response to HGF stimulation. Therefore, it was explored whether HGF/NK4 would inhibit the tyrosine phosphorylation of c-Met by HGF.

Thus, A549 cells were solubilized by stimulation with HGF and/or HGF/NK4 and immunoprecipitated with anti-c-Met antibody. Western blotting was then carried out and the tyrosine phosphorylation of c-Met was studied using anti-phosphotyrosine antibody.

As a result, whereas the stimulation with HGF (110 pM) was found to induce the tyrosine phosphorylation of c-Met, the stimulation with HGF/NK4 (110 nM) induced little phosphorylation. Moreover, HGF/NK4 dose-dependently inhibited the HGF-induced tyrosine phosphorylation of c-Met.

The above results indicated that HGF/NK4 inhibits the HGF-induced tyrosine phosphorylation of c-Met/HGF receptors. It was also suspected that, based on this inhibitory action, HGF/NK4 antagonizes the biological activity of HGF.

EXAMPLE 7 INHIBITORY EFFECT OF HGF/NK4 ON GROWTH OF VASCULAR ENDOTHELIAL CELLS

Using human lung microvascular endothelial cells (HMVEC-L; Clonetics) and human dermal microvascular endothelial cells (HMVEC-D; Clonetics) as tester vascular endothelial cells, the growth inhibitory effect of HGF/NK4 on endothelial cells was evaluated.

Thus, using human lung microvascular endothelial cells or human skin microvascular endothelial cells in the logarithmic phase of growth of passage 5~8, a cell suspension was prepared and a gelatin-coated 24-well plate was seeded with 8000 cells per well. After 24 hours, the medium was changed to the fresh one (a 1:1 mixture of EGM (Eagle General Medium) and DMEM (Dulbecco's Modified Eagle Medium) supplied with 5% serum), and four groups of 3 ng/ml bFGF (basic fibroblast growth factor), 10 ng/ml HGF, 10 ng/ml VEGF (vascular endothelial growth factor) and negative control (5% serum-containing solution; None on the drawing) were established. Then, HGF/NK4 in a varying concentration of 0 to 450 nM was added and the plate was incubated under 5% CO₂ at 37°C.

After 72 hours, the cells were detached by trypsin coating and counted using a Coulter counter.

The results for human lung microvascular endothelial cells are shown in Fig. 5 and those for human skin microvascular endothelial cells are shown in Fig. 6.

It can be seen from these diagrams that HGF/NK4 inhibits growth of vascular endothelial cells as induced by stimulation with 3 ng/ml bFGF, 10 ng/ml HGF, 10 ng/ml VEGF and 5% serum, respectively, all concentration-dependently and significantly. These results suggested that HGF/NK4 acts in an inhibitory way not only against HGF-induced growth of vascular endothelial cells but also against the growth induced by other vascular endothelial cell growth factors such as bFGF and VEGF.

EXAMPLE 8 EFFECTS OF ANTI-HGF ANTIBODY AND HGF/NK4 ON HUMAN CAPILLARY VESSEL ENDOTHELIAL CELLS

A. INFLUENCE ON CELL GROWTH

The effects of anti-HGF antibody and HGF/NK4 on growth of human capillary vessel endothelial cells were evaluated.

METHOD

Cultured human skin capillary vessel endothelial cells were washed with phosphate-buffered saline (PBS) and detached with trypsin-EDTA (phosphate-buffered saline (PBS) containing 0.05% trypsin and 0.02% EDTA). These endothelial cells were suspended in EBM-2 medium (Clonetics) supplemented with 5% fetal bovine serum (FBS), seeded on a gelatin-coated 24-well plate at a density of 5×10^3 cells/cm² and cultured for 24 hours.

The culture was divided into 10 groups according to the following 10 kinds of media based on 5% FBS-EBM-2 medium and the culture medium was changed to the respective

media. The symbol α -HGF Ab which appears below stands for anti-HGF rabbit polyclonal antibody.

1. 5% FBS
2. 5% FBS + 3 ng/ml bFGF
3. 5% FBS + 3 ng/ml bFGF + 300 nM HGF/NK4
4. 5% FBS + 3 ng/ml bFGF + 10 μ g/ml α -HGF Ab
5. 5% FBS + 10 ng/ml VEGF
6. 5% FBS + 10 ng/ml VEGF + 300 nM HGF/NK4
7. 5% FBS + 10 ng/ml VEGF + 10 μ g/ml α -HGF Ab
8. 5% FBS + 3 ng/ml HGF
9. 5% FBS + 3 ng/ml HGF + 300 nM HGF/NK4
10. 5% FBS + 3 ng/ml HGF + 10 μ g/ml α -HGF Ab

These media were incubated at 37°C under 5% CO₂ for 72 hours, after which time the cells were detached by trypsin coating and counted with a Coulter counter.

RESULTS

The results are shown in Fig. 7. It can be seen from the diagram that 300 nM HGF/NK4 definitely inhibited growth of vascular endothelial cells as promoted by stimulation with 3 ng/ml bFGF, 10 ng/ml VEGF and 3 ng/ml HGF, respectively. On the other hand, 10 μ g/ml anti-HGF rabbit polyclonal antibody specifically inhibited the HGF-stimulated growth of vascular endothelial cells but did not inhibit the growth of vascular endothelial cells stimulated with bFGF or VEGF. These results suggested that, aside from the HGF-antagonizing action, HGF/NK4 inhibits growth of vascular endothelial cells through some other novel activity.

B. INFLUENCE ON CELL MIGRATION

The effects of anti-HGF antibody and HGF/NK4 on migration of human capillary vessel endothelial cells were evaluated.

METHOD

The effect on cell migration was studied by the Boiden chamber method (Yoshida, A. et al., Growth Factors, 1996; 13(1-2): 57-64). Thus, the Boiden chamber test was carried out using a polycarbonate filter with a pore size of 5 μ m which had been coated with 13.4 μ g/ml of fibronectin.

First, human capillary vessel endothelial cells were cultured in serum-free EBM-2 medium for 12 hours and suspended in EBM-2 containing 1% fetal bovine serum and the suspension was seeded on said filter at a density of 12×10^4 cells/cm².

The culture was divided into 10 groups, and bFGF, HGF, VEGF, HGF/NK4 and anti-HGF rabbit polyclonal antibody (α -HGF Ab) were respectively added to the external fluid of the filter cup in these groups as follows.

1. None (1% FBS-EBM-2 medium)
2. 3 ng/ml bFGF
3. 3 ng/ml bFGF + 300 nM HGF/NK4
4. 3 ng/ml bFGF + 10 μ g/ml α -HGF Ab
5. 10 ng/ml VEGF
6. 10 ng/ml VEGF + 300 nM HGF/NK4
7. 10 ng/ml VEGF + 10 μ g/ml α -HGF Ab
8. 3 ng/ml HGF
9. 3 ng/ml HGF + 300 nM HGF/NK4

10. 3 ng/ml HGF + 10 μ g/ml α -HGF Ab

These samples were incubated for 5 hours and the number of cells (per visual field) which had migrated to the underside of the filter was determined under the microscope ($\times 200$). For improved accuracy of determination, cell counting was performed in 5 randomly selected visual fields.

RESULTS

The results are shown in Fig. 8. It is apparent from the diagram that 300 nM HGF/NK4 definitely inhibited the migration of vascular endothelial cells stimulated by 3 ng/ml bFGF, 10 ng/ml VEGF or 3 ng/ml HGF. On the other hand, 10 μ g/ml anti-HGF rabbit polyclonal antibody specifically inhibited the HGF-stimulated migration of vascular endothelial cells but did not inhibit the bFGF or VEGF-stimulated migration of these cells. Those results suggested that, in addition to HGF-antagonizing activity, HGF/NK4 inhibits migration of vascular endothelial cells through some other novel activity.

EXAMPLE 9: INHIBITORY EFFECT OF HGF/NK4 ON THE NEOVASCULARIZATION OF CHICK CHORIOALLANTOIC MEMBRANE (CAM)

Fertile chicken eggs were incubated for 4 days, after which the eggshell was drilled in two positions, namely over the air chamber and the lateral side of the shell. From the side hole, 3 ml of the egg white was aspirated and the shell was sealed with a tape. The shell and shell membrane over the air chamber were removed and a silicone ring was set centrally on the chorioallantoic membrane (CAM). Then, an HGF/NK4- or bovine serum albumin (control)-containing methylcellulose disk was set in the silicone ring. After 2 days of incubation at 37°C, the vasculature on the CAM was examined with a stereoscopic microscope. The results are shown in Table 1.

Table 1

Degree of neovascular invasion	
HGF/NK4	+
Control	+++

The degree of neovascular invasion into the disk was evaluated on the following scale.

-: no invasion

+: about 1~2 invading vessels

++: about 3~4 invading vessels

+++: 5 or more invading vessels

The photographs of the findings obtained in the examination with a stereoscopic microscope, in lieu of a drawing, are presented in Fig. 9.

It will be apparent that whereas the control disk showed a marked neovascular invasion, the HGF/NK4 disk showed little evidence of neovascular invasion. This finding indicated that HGF/NK4 has neovascularization inhibitory activity.

EXAMPLE 10: INHIBITORY EFFECT OF HGF/NK4 ON TUMOR NEOVASCULARIZATION

Using 6~8-week-old nude mice (BALB/c nu/nu), 5×10^6 GB-d1 human gallbladder cancer cells were transplanted subcutaneously in the dorsal region. After 7 days, an osmotic pressure pump (Alzet) containing HGF/NK4 or, as control, saline was implanted beneath the dorsal skin and HGF/NK4 or saline was continuously infused into the vicinity of the transplanted cancer cells for 13 days. At week 4 after transplantation, the tumor mass was excised, fixed and sectioned in the routine manner to prepare a tissue specimen. For evaluating neovascularization in the cancer tissue, the tissue section was stained by the

immunohistochemical method using anti-von Willebrand factor antibody (Dako). The results are shown in Table 2.

Table 2

von Willebrand factor stain	
HGF/NK4	+
Control	+++

The degree of neovascularization in the cancer tissue was evaluated on the following scale.

- : no von Willebrand factor-positive microvessels
- + : about 1/4 of microvessels are von Willebrand factor-positive
- ++ : about 1/2 of microvessels are von Willebrand factor-positive
- +++ : about 3/4 of microvessels are von Willebrand factor-positive
- ++++ : more than 3/4 of microvessels are von Willebrand factor-positive

Moreover, the findings in the microscopic examination are presented as photographs, in lieu of a drawing [Fig. 10].

It will be apparent from the above results that a large number of von Willebrand factor-positive microvessels were found in the control saline-infused graft tumor tissue, with no evidence of apoptosis of cancer cells in the tumor mass. In contrast, in the HGF/NK4-perfused graft tumor tissue, tumor neovascularization was remarkably inhibited, with evidence of an extensive apoptosis of cancer cells in the center of the tumor mass. These results indicated that HGF/NK4 inhibits tumor neovascularization *in vivo*[[*in vivo*]].

REFERENCE EXAMPLE 1 INHIBITORY EFFECT OF HGF/NK4 ON TUMOR GROWTH AND METASTASIS (1)

Using 6~8-week-old nude mice (BALB/c nu/nu), 5×10^6 Lewis lung cancer cells were transplanted subcutaneously at the animal back. After 5 days, an osmotic pressure pump (Alzet) containing

HGF/NK4 or saline (control) was implanted beneath the dorsal skin and HGF/NK4 or saline was continuously infused into the neighborhood of the tumor graft for 2 weeks. At 28 days after transplantation, the weight and pulmonary metastasis of the transplanted tumor were investigated. The tumor volume was calculated by means of the formula: (minor diameter)² × (major diameter) × 0.5.

The time course of tumor volume is shown in Fig. 11 A and the weight of the transplanted tumor at day 28 is shown in Fig. 11 B. It will be apparent from these diagrams that whereas the transplanted tumor perfused with saline showed rapid growth at 10 days after transplantation and onwards, HGF/NK4 inhibited tumor growth strongly and dose-dependently.

Regarding the pulmonary metastasis of Lewis lung cancer, whereas a large number of pulmonary metastatic foci were observed in the control saline-perfused group, pulmonary metastasis was inhibited remarkably and dose-dependently in the animals perfused with HGF/NK4 (Fig. 12 A, B).

These results indicated that HGF/NK4 has an action to significantly inhibit the growth and metastasis of lung cancer *in vivo*[[*in vivo*]].

REFERENCE EXAMPLE 2 INHIBITORY EFFECT OF HGF/NK4 ON CANCER GROWTH AND METASTASIS (2)

Using 6~8-week-old nude mice (BALB/c nu/nu), 5×10^6 Jyg mammary cancer cells were transplanted subcutaneously in the dorsal region. After 5 days, an osmotic pressure

pump (Alzet) containing HGF/NK4 or saline (control) was implanted beneath the dorsal skin and HGF/NK4 or saline was continuously infused into the neighborhood of the transplanted tumor for 2 weeks. The volume of the tumor graft was serially measured and the number of metastatic foci on the lung surface was counted at 28 days after transplantation.

The time course of tumor volume is shown in Fig. 13 A and the number of metastatic foci on the lung surface at day 28 after transplantation is shown in Table 13 B. It will be apparent that whereas the control tumor perfused with saline showed rapid growth at day 10 after transplantation and onwards, HGF/NK4 suppressed growth of the tumor. Regarding pulmonary metastasis, whereas a large number of pulmonary metastatic foci were observed in the control saline-perfused group, pulmonary metastasis was inhibited in the animals perfused with HGF/NK4.

These results indicated that HGF/NK4 has an action to inhibit the growth and metastasis of Jyg mammary cancer significantly *in vivo*[[*in vivo*]].

FORMULATION EXAMPLE 1

A solution containing the HGF/NK4 prepared in Example 1 (1 mg), mannitol (1 g) and polysolvate 80 (10 mg) in 100 ml of saline was aseptically prepared and distributed into vials, 1 ml per vial. The vial contents were lyophilized and the vials sealed to provide the neovascularization inhibitor of the invention in the form of a lyophilizate.

FORMULATION EXAMPLE 2

An aqueous solution containing 1 mg of the HGF/NK4 prepared in Example 1 and 100 mg of human serum albumin was aseptically formulated with 100 ml of 0.02 M phosphate buffer (containing 0.15 M NaCl and 0.01% polysolvate 80; pH 7.4) and the mixture was distributed into vials, 1 ml per vial. The liquid contents of the vials were

lyophilized and the vials sealed to provide the neovascularization inhibitor in the form of a lyophilizate.

FORMULATION EXAMPLE 3

A solution containing the HGF/NK4 prepared in Example 1 (1 mg), sorbitol (2 g), glycine (2 g) and polysolvate 80 (10 mg) in 100 ml of distilled water for injection was aseptically prepared and distributed into vials, 1 ml per vial. The contents of the vials were lyophilized and the vials sealed to provide the neovascularization inhibitor in the form of a lyophilizate.

INDUSTRIAL APPLICABILITY

The neovascularization inhibitor of the present invention finds application, based on its neovascularization inhibitory activity, as a prophylactic or therapeutic agent for various diseases associated with abnormal angiopoiesis, such as rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, senile macular degeneration, and over-cicatrizaton associated with wound healing.

CLAIMS

1. A neovascularization inhibitor comprising the following polypeptide (a) or (b) as an active ingredient:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF);

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

2. The neovascularization inhibitor according to Claim 1 wherein said polypeptide has at least one hairpin domain and 4 Kringle domains.

3. The neovascularization inhibitor according to Claim 1 wherein said polypeptide is one obtainable by elastase digestion of hepatocyte growth factor.

4. A neovascularization inhibitor comprising the polypeptide defined by SEQ ID NO: 1 and a pharmaceutically acceptable carrier.

5. A neovascularization inhibitor comprising the polypeptide defined by SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

6. A prophylactic or therapeutic drug for a disease associated with abnormal angiopoiesis which comprises the polypeptide defined in Claim 1 and a pharmaceutically acceptable carrier.

7. The prophylactic or therapeutic drug according to Claim 6 wherein said disease associated with abnormal angiopoiesis is selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eye, angiofibroma, benign tumors and wound granulation.

8. A prophylactic or therapeutic drug for a disease arising from over_stimulation of endothelial cells which comprises the polypeptide defined in claim 1 and a pharmaceutically acceptable carrier.

9. The prophylactic or therapeutic drug according to Claim 8 wherein said disease arising from over_stimulation of endothelial cells is selected from the group consisting of enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and over cicatrization.

10. A conception-regulating drug comprising the polypeptide defined in Claim 1 and a pharmaceutically acceptable carrier.

11. A method of inhibiting neovascularization which comprises administering to a subject a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF).

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

12. A method for prophylaxis or therapy of a disease associated with abnormal angiopoiesis which comprises administering a neovascularization inhibitor comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence PyrGlu³² ~ Val⁴⁷⁸ of hepatocyte growth factor (HGF).

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF to a subject in whom a prophylactic or therapeutic treatment for said disease is indicated.

13. The method for prophylaxis or therapy according to Claim 12 wherein said disease is any disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eye, angiofibroma, benign tumors, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and over_cicatrizatization.

14. Use of the following polypeptide (a) or (b) for the production of a neovascularization inhibitor:

(a) a polypeptide having the amino acid sequence $\text{PyrGlu}^{32} \sim \text{Val}^{478}$ of hepatocyte growth factor (HGF).

(b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids and having antagonistic activity against the c-Met/HGF receptor-mediated action of HGF.

ABSTRACTABSTRACT OF THE DISCLOSURE

Novel neovascularization inhibitory factors and neovascularization inhibitors useful in preventing and treating various diseases in association with neovascularization. These neovascularization inhibitors contain as the active ingredient polypeptides with the following definition (a) or (b): (a) a polypeptide having an amino acid sequence of PyrGlu³²-Val⁴⁷⁸ in HGF (hepatocyte growth factor); or (b) a polypeptide having an amino acid sequence derived from the amino acid sequence as defined in (a) by deletion, substitution or addition of one or several amino acids and having an antagonism to the effect of HGF via c-Met-HGF receptor.